


## Taurohyodeoxycholic acid sodium

<b>Cat. No.:</b>	HY-114360A
<b>CAS No.:</b>	38411-85-7
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>44</sub> NNaO <sub>6</sub> S
<b>Molecular Weight:</b>	522
<b>Target:</b>	Interleukin Related; TNF Receptor
<b>Pathway:</b>	Immunology/Inflammation; Apoptosis
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 62.5 mg/mL (119.73 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.9157 mL	9.5785 mL	19.1571 mL
	5 mM	0.3831 mL	1.9157 mL	3.8314 mL
	10 mM	0.1916 mL	0.9579 mL	1.9157 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Taurohyodeoxycholic acid (THDCA) sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. Taurohyodeoxycholic acid can also reduce the activity and expression of myeloperoxidase TNF- $\alpha$  and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model.

#### IC<sub>50</sub> & Target

IL-6

TNFR1

#### In Vivo

Taurohyodeoxycholic acid reduces the size and weight of human gallstones in vitro. Taurohyodeoxycholic acid increases bile flow, bile cholesterol secretion and bile lipid secretion in rats. Co-administration of Taurohyodeoxycholic acid and Taurochenodeoxycholic acid prevented Taurohyodeoxycholic acid-induced hepatotoxicity and increased bile flow and bile acid and phospholipid secretion in rats.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. *Hepatology*. 1998 Feb;27(2):520-5.

- 
- [2]. Angelico M, et al. Dissolution of human cholesterol gallstones in bile salt/lecithin mixtures: effect of bile salt hydrophobicity and various pHs. *Scand J Gastroenterol.* 1995 Dec;30(12):1178-85.
- [3]. Angelico M, et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretion in the rat. *Dig Dis Sci.* 1994 Nov;39(11):2389-97.
- [4]. Roda A, et al. Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rat. *Hepatology.* 1998 Feb;27(2):520-5.
- [5]. Solmon Kusuma S, et al. Antineoplastic activity of monocrotaline against hepatocellular carcinoma[J]. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*, 2014, 14(9): 1237-1248.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA